UNSPSC 51284301: Azidamfenicol

This classification denotes an antibiotic with the molecular formula C11H13N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40257685LM, chemically known as acetamide, 2-azido-n-(beta-hydroxy-alpha-(hydroxymethyl)-p-nitrophenethyl)-, d-threo-(-)- but generally known as azidamfenicol, which bears US NIH Compound Identifier 62858. European Medicines Agency schedules Azidamfenicol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05654MIG.

UNSPSC 51284301 Azidamfenicol is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent opportunities show little activity explicitly tagged to this code. The two most recent records in the state and local market reflect broader pharmaceutical and medical-supply purchasing: the Illinois Department of Public Health awarded a piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) under an IFB process, and Seminole County, Florida released an IFB for naloxone and drug deactivation systems through competitive bidding. Neither opportunity directly involves azidamfenicol, suggesting the code itself sees minimal recent state and local solicitation activity or is applied inconsistently in the market.

Activity under the code appears concentrated in Florida and Illinois among health departments and county public-health entities. The Illinois Department of Public Health contract, valued at $2,999,999.11 over the three-year life including renewals, used cooperative purchasing (MMCAP Infuse) and an IFB with a 12-month initial term and renewal options. Seminole County's procurement called for 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to a community health building, required e-Procurement Portal submission, and included a two-year initial term with a one-year renewal option. No set-aside preferences were documented in either opportunity. The code shows limited recent state and local activity; firms pursuing pharmaceutical supply contracts in this space may find better alignment with higher-level family or class codes that capture the full scope of pharmaceutical procurement.